The relationship between elevated systemic blood pressure and AMD has been analyzed in clinical trials; however, research has concentrated on the evaluation of AH as a risk factor for the development of AMD, not the effects of anti-VEGF treatment. The gene discussed is VEGFA; the disease is age-related macular degeneration.